Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab

BMC Musculoskeletal Disorders

Volumn 16, Issue 1, 2015, Pages

  Lorenzin, Mariagrazia ^a   Ortolan, Augusta ^a   Frallonardo, Paola ^a   Oliviero, Francesca ^a   Punzi, Leonardo ^a   Ramonda, Roberta ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Ankylosing spondylitis; anti TNF agents; Biologic drugs; Infliximab; Spondyloarthritis

Indexed keywords

INFLIXIMAB; STEROID; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR;

ABDOMINAL PAIN; ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDILITIS METROLOGY INDEX; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; BRONCHITIS; BRONCHOPNEUMONIA; COMMON COLD; CONJUNCTIVITIS; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EYE DISEASE; FEMALE; HEADACHE; HERPES LABIALIS; HUMAN; HYPERTENSIVE CRISIS; INFLAMMATORY DISEASE; INFLUENZA; INJECTION SITE REACTION; LARYNGITIS; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE ASSESSMENT; OTITIS; PHARYNGITIS; RETROSPECTIVE STUDY; RHINOSINUSITIS; SEX DIFFERENCE; SKIN INFECTION; SURVIVAL; TACHYCARDIA; TOOTH INFECTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UVEITIS; VAGINITIS; VERTIGO; ANTAGONISTS AND INHIBITORS; DISABILITY; IMMUNOLOGY; ITALY; MIDDLE AGED; REMISSION; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TIME FACTOR;

ADULT; DISABILITY EVALUATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLIXIMAB; ITALY; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84937963749     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/s12891-015-0620-4     Document Type: Article

References (40)

1. Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377:2127-37.
2. Ramonda R, Lorenzin M, Lo Nigro A, Vio S, Zucchetta P, Frallonardo P, et al. Anterior chest wall involvement in early stages of spondyloarthritis: advanced diagnostic tools. J Rheumatol. 2012;39:1844-49.
3. Frallonardo P, Ramonda R, Lo Nigro A, Modesti V, Campana C, Punzi L. La storia naturale della spondilite anchilosante nel XXI secolo. The natural history of ankylosing spondylitis in the 21st century. Reumatismo. 2011;63:49-54.
4. Rachid B, El Zorkany B, Youseif E, Tikly M. Early diagnosis and treatment of ankylosing spondylitis in Africa and the Middle East. Clin Rheumatol. 2012;31:1633-39.
5. Dougados M, Dijkmans B, Khan M, Maksymowych W, van der Linden S, Brandt J. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis. 2002;61Suppl 3:iii40-50.
6. Braun J, van der Heijde D. Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides. Expert Opin Investig Drugs. 2003;12:1097-99.
7. Chen J, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev. 2006;4, CD004524.
8. Braun J, Zochling J, Baraliakos X, Alten R, Burmester G, Grasedyck K, et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicenter randomized controlled trial. Ann Rheum Dis. 2006;65:1147-53.
9. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70:896-904.
10. Coates LC, Cawkwell LS, Ng NW, Bennett AN, Bryer DJ, Fraser AD, et al. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology (Oxford). 2008;47:897-900.
11. Baraliakos X, van den Berg R, Braun J, van der Heijde D. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. Rheumatology (Oxford). 2012;51:1378-87.
12. Konsta M, Sfikakis PP, Bournia VK, Karras D, Iliopoulos A. Absence of radiographic progression of hip arthritis during infliximab treatment for ankylosing spondylitis. Clin Rheumatol. 2013;32:1229-32.
13. Arturi P, Schneeberger EE, Sommerfleck F, Buschiazzo E, Ledesma C, Maldonado Cocco JA, et al. Adherence to treatment in patients with ankylosing spondylitis. Clin Rheumatol. 2013;32:1007-15.
14. Hammoudeh M, Alarfaj A, Chen DY, Djoudi H, Youseif E, Zhu J. Safety of tumor necrosis factor inhibitors use for rheumatoid arthritis and ankylosing spondylitis in Africa, the Middle East, and Asia: focus on severe infections and tuberculosis. Clin Rheumatol. 2013;32:293-300.
15. Dischereit G, Tarner IH, Müller-Ladner U, Lange U. Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study. Clin Rheumatol. 2013;32:377-81.
16. Healey EL, Haywood KL, Jordan KP, Garratt AM, Packham JC. Patients with well establishedankylosing spondylitis show limited deterioration in a ten-year prospective cohort study. Clin Rheumatol. 2013;32:67-72.
17. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Long-term efficacy andsafety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extensionstudy of a three-month, randomized, placebo-controlled trial. Arthritis Rheum. 2003;48:2224-33.
18. Breban M, Vignon E, Claudepierre P, Devauchelle V, Wendling D, Lespessailles E, et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford). 2002;41:1280-85.
19. Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis. 2008;67:340-5.
20. Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther. 2011;13:R94.
21. Saougou I, Markatseli TE, Voulgari PV, Drosos AA. Maintained clinical response of infliximab treatment in anylosing spondylitis: A 6-year long-term study. Joint Bone Spine. 2010;77:325-29.
22. Venetsanopoulou AI, Voulgari PV, Alamanos Y, Papadopoulos CG, Markatseli TE, Drosos AA. Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis. Rheumatol Int. 2007;27:935-39.
23. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361-68.
24. Godfrin-Valnet M, Prati C, Puyraveau M, Toussirot E, Letho-Gyselink H, Wendling D. Evaluation of spondylarthritis activity by patients and physicians: ASDAS, BASDAI, PASS, and flares in 200 patients. Joint Bone Spine. 2013;80:393-98.
25. Boonen A, van der Heijde D, Severens JL, Boendermaker A, Landewé R, Braun J, et al. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis. Ann Rheum Dis. 2006;65:201-8.
26. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis Jr. JC, Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2006;65:442-52.
27. Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester GR, et al. Persistent clinical efficacy andsafety of infliximab in ankylosing spondylitis after 8 years-early clinical response predicts long term outcome. Rheumatology (Oxford). 2011;50:1690-9.
28. Spadaro A, Lubrano E, Marchesoni A, D'Angelo S, Ramonda R, Addimanda O, et al. Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study. Rheumatology (Oxford). 2013;52:1914-19.
29. Bunchuk NV, Rumiantseva OA, Loginova EI, Bochkova AG, Storozhakov GI, Ettinger OA, et al. The efficacy and safety of infliximab in patients with ankylosing spondylitis: results of an open-labeled multicenter study. Ter Arkh. 2010;82:41-6.
30. Pavelka K, Forejtová S, Stolfa J, Chroust K, Buresová L, Mann H, et al. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clin Exp Rheumatol. 2009;27:958-63.
31. Bodur H, Ataman S, Buʇdaycl DS, Rezvani A, Nas K, Uzunca K, et al. Description of the registry of patients with ankylosing spondylitis in Turkey: TRASD-IP. Rheumatol Int. 2012;32:169-76.
32. Glintborg B, Østergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2013;72:1149-55.
33. Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, Sieper J, et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis. 2007;66:910-15.
34. Masiero S, Bonaldo L, Pigatto M, Lo Nigro A, Ramonda R, Punzi L. Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy: a randomized controlled trial. J Rheumatol. 2011;38:1335-42.
35. Ciprian L, Lo Nigro A, Rizzo M, Gava A, Ramonda R, Punzi L, et al. The effects of combined spa therapy and rehabilitation on patients with ankylosing spondylitis being treated with TNF inhibitors. Rheumatol Int. 2013;33:241-5.
36. Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis. 2010;69:2002-8.
37. Modesti V, Ramonda R, Ortolan A, Lorenzin M, Lo Nigro A, Frallonardo P, et al. Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study. Scand J Rheumatol. 2012;41:490-1.
38. Maksymowych WP, Jhangri GS, Lambert RG, Mallon C, Buenviaje H, Pedrycz E, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol. 2002;29:959-65.
39. Giardina AR, Ferrante A, Ciccia F, Impastato R, Miceli MC, Principato A, et al. A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. Rheumatol Int. 2010;30:1437-40.
40. Spadaro A, Punzi L, Marchesoni A, Lubrano E, Mathieu A, Cantini F, et al. Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. Rheumatology (Oxford). 2010;49:1107-11.